Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2026)

Enanta Pharmaceuticals (ENTA) has 8 years of Operating Leases data on file, last reported at $52.8 million in Q1 2026.

• Quarterly Operating Leases fell 6.65% year-over-year to $52.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.8 million (down 6.65% YoY) and the FY2025 annual result came in at $54.8 million, up 1.51% from the prior year.
• Operating Leases eased to $52.8 million in Q1 2026, from $53.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $56.5 million in Q1 2025 to a low of $15.1 million in Q1 2022.
• A 5-year average of $37.9 million and a median of $43.4 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases surged 1886.86% — and 2026, when it dropped 6.65%.
• Tracing ENTA's Operating Leases over 5 years: stood at $21.9 million in 2022, then retreated by 6.11% to $20.5 million in 2023, then soared by 175.06% to $56.5 million in 2024, then retreated by 4.73% to $53.8 million in 2025, then dropped by 1.87% to $52.8 million in 2026.
• The last three Operating Leases figures came in at $52.8 million (Q1 2026), $53.8 million (Q4 2025), and $54.8 million (Q3 2025), per Business Quant data.